DocDollars

Ibsa Institut Biochimique SA

Switzerland · Reporting entity ID 100000061369

Total reported 2019–2025
$21.9M
#301 of 2,960 reporting companies — 0% of all reported industry payments
$274K in general payments across 128 records, plus $21.6M in research funding across 750 records.

How it breaks down

General payments $274,104
Research funding $21,622,586

Where this comes from

Figures are from the CMS Open Payments “payments grouped by reporting entity” dataset, queried live. Reporting entities are applicable manufacturers and group purchasing organisations required to report under the Sunshine Act.

Summary

Ibsa Institut Biochimique SA reported $21.9M to US doctors and teaching hospitals from 2019 to 2025, ranking #301 of 2,960 reporting companies. 99% of that was research funding and 1% general payments such as consulting, speaking, food and travel. 128 general payment records and 750 research records were filed.

Common questions about Ibsa Institut Biochimique SA

How much has Ibsa Institut Biochimique SA paid US doctors?

Ibsa Institut Biochimique SA reported $21,896,691 to US physicians and teaching hospitals across the 2019–2025 Open Payments program years: $274,104 in general payments, $21,622,586 in research funding.

How does Ibsa Institut Biochimique SA rank among drug and device companies?

It ranks #301 of 2,960 reporting entities by total reported value, about 0% of all industry payments in the dataset.

Does a payment from Ibsa Institut Biochimique SA mean a doctor did something wrong?

No. Open Payments records transfers of value such as speaking fees, consulting, meals, travel and research funding. The data shows the relationship, not its effect on prescribing or care.